PubMed
Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline
Molitch ME, Clemmons DR, Malozowski S, et al. J Clin Endocrinol Metab. 2011
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 53% · Mixed 34% · Unfavorable overall 13%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.01–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 63% said they felt similar to their last entry, 39% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 19 days · Based on 20 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 47% · Mixed 34% · Unfavorable overall 19%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 1–2 mg · Most common: 0.6–1 mg
Reports span 0.2–5 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 31 days · Based on 111 repeat reporters
Published sources linked on the HGH (Somatropin) and MK-677 wiki pages.
PubMed
Molitch ME, Clemmons DR, Malozowski S, et al. J Clin Endocrinol Metab. 2011
PubMed
Mameli C, Orso M, Calcaterra V, et al. Pharmacological research. 2023
PubMed
Colao A, Grasso LFS, Giustina A, et al. Nature reviews. Disease primers. 2019
PubMed
Murphy MG, Plunkett LM, Gertz BJ, et al. J Clin Endocrinol Metab. 1998
PubMed
Nass R, Pezzoli SS, Oliveri MC, et al. J Clin Endocrinol Metab. 2008
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Murphy MG, Plunkett LM, Gertz BJ, et al. The Journal of clinical endocrinology and metabolism. 1998
PubMed
Philip M, Karakka Kal AK, Subhahar MB, et al. Rapid communications in mass spectrometry : RCM. 2022